Luspatercept

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thalassemia

Conditions

Thalassemia

Trial Timeline

Feb 5, 2018 → Nov 28, 2022

NCT ID

NCT03342404

About Luspatercept

Luspatercept is a phase 2 stage product being developed by Merck for Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03342404. Target conditions include Thalassemia.

What happened to similar drugs?

7 of 17 similar drugs in Thalassemia were approved

Approved (7) Terminated (2) Active (10)

✅DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

🔄deferasiroxNovartisPhase 3

🔄ICL670 + deferoxamineNovartisPhase 3

✅Zoledronic AcidNovartisApproved

✅DeferasiroxNovartisApproved

🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03342404	Phase 2	Completed	Feb 5, 2018	Nov 28, 2022	Thalassemia
NCT02604433	Phase 3	Completed	May 2, 2016	Jan 5, 2021	Erythrocyte Transfusion
NCT02631070	Phase 3	Completed	Feb 9, 2016	Nov 26, 2020	Myelodysplastic Syndromes
NCT02268409	Phase 2	Completed	Oct 20, 2014	Jun 18, 2020	β-Thalassemia
NCT02268383	Phase 2	Completed	Oct 9, 2014	Mar 19, 2020	Myelodysplastic Syndromes
NCT01749540	Phase 2	Completed	Feb 28, 2013	Nov 11, 2015	B-Thalassemia
NCT01749514	Phase 2	Completed	Jan 21, 2013	Oct 22, 2018	Anemia

Competing Products

20 competing products in Thalassemia

See all competitors

Product	Company	Stage	Hype Score
luspatercept	Merck	Phase 2	35
ACE-536	Merck	Phase 2	42
luspatercept	Merck	Phase 2	35
Deferasirox	Novartis	Approved	43
Blood sample	Novartis	Pre-clinical	26
deferasirox + placebo	Novartis	Phase 2	35
Zoledronic acid + Placebo	Novartis	Phase 2/3	34
deferasirox	Novartis	Approved	35
deferasirox	Novartis	Phase 3	40
ICL670 + deferoxamine	Novartis	Phase 3	40
ruxolitinib	Novartis	Phase 2	35
Deferasirox	Novartis	Phase 2	35
Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)	Novartis	Phase 2	35
Zoledronic Acid	Novartis	Approved	43
Deferasirox	Novartis	Phase 2	27
Deferasirox	Novartis	Approved	35
Deferasirox + Deferoxamine (DFO)	Novartis	Phase 2	27
Deferasirox	Novartis	Phase 1	29
Deferasirox	Novartis	Phase 3	40
Deferasirox	Novartis	Phase 2	35